8/19/2019  3:13:38 PM Chg. +1.56 Volume Bid4:07:23 PM Ask4:07:23 PM Market Capitalization Dividend Y. P/E Ratio
75.18EUR +2.12% 0
Turnover: 0.00
75.59Bid Size: 500 75.83Ask Size: 500 16.12 bill.EUR - -

Business description

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
 

Management board & Supervisory board

CEO
Hervé Hoppenot
Management board
Christiana Stamoulis, Barry P. Flannelly, Dash Dhanak, Dr. Lothar H. Finke, Dr. Wenqing Yao, Jonathan E. Dickinson, Maria E. Pasquale, Michael Morrissey, Paula J. Swain, Steven H. Stein, M.D., Vijay Iyengar, M.D.
Supervisory board
Hervé Hoppenot, Dr. Jacqualyn A. Fouse, Dr. Wendy Dixon, Jean-Jacques Bienaimé, Julian C. Baker, Paul A. Brooke, Paul A. Friedman, M.D., Paul J. Clancy
 

Company data

Name: Incyte Corporation
Address: 1801 Augustine Cut-Off,Wilmington, DE 19803, USA
Phone: +1-302-498-6700
Fax: -
E-mail: -
Internet: www.incyte.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 44.60%
IPO date: -

Investor relations

Name: Michael Booth
IR phone: +1-302-498-5914
IR Fax: -
IR e-mail: mbooth@incyte.com

Main Shareholders